Universal Medica Group (UMG) has reached a new stage in its development with the acquisition of BBac, a company specializing in pharmacovigilance and safety in the healthcare industry. This acquisition is part of the “Horizon 2020” strategic plan, which responds to the industry transformations and to needs of healthcare industry evolutions to promote the healthcare products proper use, safety and efficacy for patients’ benefit.
An independent company founded in 2001 by its CEO, Bertrand Bayrou MD, and its Managing Director, Joëlle Falcou, BBac has made a name for itself in the vigilance management field for independent French laboratories. This beautiful structure composed of physicians, pharmacists and scientists has never stopped evolving. Since July 16, 2018, BBac, is the fifth affiliate of Universal Medica Group alongside :
– Universal Medica, leader in Medical and Pharmaceutical Affairs : Medical Information, Vigilance Management, Quality Assurance, Real Life Studies,
– Universal Biotech, specialized in Innovation Management and promoter of the International Innovation Prize.
– Cherry for Life Science, a medical health communication agency that supports the digital transformation of our businesses by ensuring the creation of quality medical content adapted to digital communication channels for healthcare professionals and patients.
– Europharma for Life Science, specialist in training, combining educational know-how and advanced technology since 1990 (E-learning, Virtual Classroom, Mobile Learning…).
A win-win merger
Bertrand BAYROU and Joëlle FALCOU explain this merger: « Universal Medica Group offers complementary skills to those of BBac, as well as an expanded operational capacity, which will enable us to respond more fully to our customers’ requests, particularly in terms of training, audits, medical information, studies and communication. BBac’s clients will benefit from the strength of Universal Medica Group structure not only in France but also internationally. »
For Universal Medica Group, « This is a natural merger given the positioning of the two companies” says Rafi Mardachti, President of the Group “The synergies and opportunities for sharing between the different entities of the group will benefit our customers. Indeed, standardized professions such as ours require very heavy investments in terms of training, quality processes and technical structure. In a context where regulations and health authorities are more and more demanding, reaching a critical size becomes a necessity. In addition, the combination of our teams and our know-how allows us to increase our strengths tenfold and accelerate our international development, particularly in the pharmacovigilance and safety market which continues to grow. »
Download : [download id=”5812″]
